Meta-analysis of the Efficacy of Gongliuqing Capsules Combined with Mifepristone in the Treatment of Uterine Leiomyoma
- VernacularTitle:宫瘤清胶囊联合米非司酮治疗子宫肌瘤有效性的Meta分析
- Author:
Yizheng ZHONG
1
;
Jiahua HUANG
1
;
Meijun PAN
1
;
Huaqing JIANG
1
;
Hao ZHENG
1
;
Wei LI
1
;
Sijian CHEN
1
;
Yingying CAO
1
;
Fan HUANG
2
;
Fasen DENG
1
;
Weipeng SUN
1
;
Kaimin GUO
3
Author Information
1. The First Clinical College，Guangzhou University of TCM，Guangzhou 510405，China
2. Clinical Medical College of Acupuncture and Rehabilitation，Guangzhou Universit y of TCM，Guangzhou 510405，China
3. Dept. of Gynaecology，Guangzhou Women’s and Children’s Medical Center，Guangzhou 510623，China
- Publication Type:Journal Article
- Keywords:
Uterine leiomyoma;
Mifepristone;
Gongliuqing capsules;
Therapeutic efficacy;
Meta-analysis;
Trial sequential
- From:
China Pharmacy
2020;31(2):221-226
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE：To systematically evaluate therapeutic efficacy of Gongliuqing capsules combined with mifepristone in the treatment of uterine leiomyoma ，in order to provide evidence-based reference for clinical medication. METHODS ：Retrieved from Cochrane Library ，PubMed，Embase，CJFD，VIP，CBM and Wanfang database ，randomized controlled trials （RCTs）about Gongliuqing capsules combined with mifepristone （trial group ）versus mifepristone alone （control group ）in the treatment of uterine leiomyoma were collected. After literature screening and data extraction ，the quality of included literatures was evaluated with modified Jadad scale. Meta-analysis was conducted by using Stata 14.0 software，and trial sequential analysis （TSA）was performed by using TSA 0.9 software. RESULTS ：A total of 12 RCTs were included ，involving 1 210 patients. The results of Meta- analysis showed that the total response rate of trial group [RR ＝1.12，95％CI（1.00，1.26），P＜0.05] was significantly higher than that of control group ；maximum uterine leiomyoma volume after treatment [SMD ＝－1.08，95％CI（－1.21，－0.95），P＜0.05]，uterine volume after treatment [SMD ＝－0.80，95％CI（－1.14，－0.45）， P＜0.05]，follicle stimulating hormone （FSH）level [SMD ＝ － 0.28，95％ CI（－ 0.45，－ 0.19），P＜0.05]，luteinizing hormone（LH）level [SMD ＝－0.44，95％CI（－0.52，－0.12）， 020-38076311。E-mail：867203217@qq.com P＜0.05]，E2 level [SMD ＝－2.69，95％CI（－3.08，－1.49）， P＜0.05] and progesterone （P）level [SMD ＝－1.27，95％CI（－1.69，－0.71），P＜0.05] of trial group were significantly lower or better than those of control group. Results of subgroup analysis showed that except for the level of FSH in 5 and 10 mg mifepristone groups （P＞0.05），maximum uterine leiomyoma volume after treatment ，uterine volume after treatment ，the levels of FSH，LH，E2 and P in trial group were significantly lower than control group. The results of TSA showed that there were definite evidences for total response rate of Gongliuqing capsules combined with mifepristone being better in the treatment of hysteromyoma. CONCLUSIONS ：Total response rate of Gongliuqing capsules combined with mifepristone in the treatment of hysteromyoma is better than mifepristone alone ，which can effectively decrease the volume of maximum uterine leiomyoma volume and uterine vilume ，and reduce the level of serum hormone.
